Data / Drug companies / Actavis Pharma, Inc.
Actavis Pharma, Inc.: 243 products in the FDA NDC directory, labeler code 0591
Actavis Pharma, Inc. (labeler code 0591) lists 243 products in the FDA National Drug Code Directory, covering 78 finished drugs by generic name. By type: 153 prescription drugs, 89 drugs for further processing. Its main marketing category is generic drugs (ANDA). The newest product started marketing on August 27, 2025.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 0591
- Products in commercial distribution
- 243
- Packages
- 360
- Finished drugs by generic name
- 78
- Prescription products
- 153
- Over the counter products
- 1
- Controlled substance products
- Schedule II 7, Schedule III 9, Schedule IV 6
- Flagged as original packager
- 133 of 133 products that carry the flag
- Started marketing in the last 12 months
- 0
- Products with a marketing end date set
- 32
- Earliest marketing start
- September 19, 1973
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 140 | 57.6% |
| Drugs for further processing | 89 | 36.6% |
| Authorized generics (NDA) | 11 | 4.5% |
| New drug applications (NDA) | 3 | 1.2% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 153 | 63% |
| Drugs for further processing | 89 | 36.6% |
| Over the counter drugs | 1 | 0.4% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 95 | 39.1% |
| Capsule | 43 | 17.7% |
| Tablet, film coated | 35 | 14.4% |
| Capsule, extended release | 11 | 4.5% |
| Tablet, film coated, extended release | 9 | 3.7% |
| Tablet, extended release | 9 | 3.7% |
| Gel | 7 | 2.9% |
| Tablet, delayed release | 6 | 2.5% |
| Capsule, gelatin coated | 5 | 2.1% |
| Patch | 5 | 2.1% |
| Cream | 3 | 1.2% |
| Solution | 2 | 0.8% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Bupropion hydrochloride | 0591-3543 | Tablet, film coated, extended release | Drugs for further processing | August 27, 2025 |
| Naloxone Hydrochloride | 0591-3871 | Spray, metered | Generic drugs (ANDA) | January 17, 2025 |
| Nizatidine | 0591-3137 | Capsule | Drugs for further processing | October 29, 2024 |
| Dicyclomine hydrochloride | 0591-0794 | Capsule | Drugs for further processing | June 24, 2024 |
| Mifepristone | 0591-4390 | Tablet, film coated | Generic drugs (ANDA) | January 19, 2024 |
| Dicyclomine hydrochloride | 0591-0795 | Tablet | Drugs for further processing | January 4, 2024 |
| Dalfampridine | 0591-2533 | Tablet, film coated, extended release | Generic drugs (ANDA) | May 31, 2022 |
| Scopolamine | 0591-2258 | System | Generic drugs (ANDA) | May 12, 2022 |
| Bexarotene | 0591-2832 | Capsule, liquid filled | Generic drugs (ANDA) | November 11, 2021 |
| Isotretinoin | 0591-2501 | Capsule | Generic drugs (ANDA) | April 29, 2021 |
| Isotretinoin | 0591-2451 | Capsule | Generic drugs (ANDA) | April 29, 2021 |
| Isotretinoin | 0591-2436 | Capsule | Generic drugs (ANDA) | April 29, 2021 |
| Isotretinoin | 0591-2435 | Capsule | Generic drugs (ANDA) | April 29, 2021 |
| Isotretinoin | 0591-2434 | Capsule | Generic drugs (ANDA) | April 29, 2021 |
| Isotretinoin | 0591-2433 | Capsule | Generic drugs (ANDA) | April 29, 2021 |
| Testosterone | 0591-2926 | Gel | Generic drugs (ANDA) | February 12, 2021 |
| Alvimopan | 0591-2312 | Capsule | Generic drugs (ANDA) | December 1, 2020 |
| Alvimopan | 0591-2312 | Capsule | Drugs for further processing | October 13, 2020 |
| Methylphenidate hydrochloride | 0591-3902 | Capsule, extended release | Generic drugs (ANDA) | September 30, 2020 |
| Methylphenidate hydrochloride | 0591-3895 | Capsule, extended release | Generic drugs (ANDA) | September 30, 2020 |
| Methylphenidate hydrochloride | 0591-3891 | Capsule, extended release | Generic drugs (ANDA) | September 30, 2020 |
| Methylphenidate hydrochloride | 0591-3873 | Capsule, extended release | Generic drugs (ANDA) | September 30, 2020 |
| Methylphenidate hydrochloride | 0591-3869 | Capsule, extended release | Generic drugs (ANDA) | September 30, 2020 |
| Methylphenidate hydrochloride | 0591-3862 | Capsule, extended release | Generic drugs (ANDA) | September 30, 2020 |
| Methylphenidate hydrochloride | 0591-3854 | Capsule, extended release | Generic drugs (ANDA) | September 30, 2020 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.